Khan Najat 4

What Happened Najat Khan, CEO, President and a director of Recursion Pharmaceuticals (RXRX), sold 28,298 shares on March 9, 2026. The weighted average sale price reported was $3.35 per share, for total proceeds of approximately $94,660. This was a sale (transaction code S), which is commonly routine and not by itself a direct signal of company outlook.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (appears timely — filed two business days after the trade).
• Price: weighted average $3.35; individual trade prices ranged from $3.32 to $3.405 (footnote F2).
• Total shares sold: 28,298; total proceeds ≈ $94,660.
• Footnote F1: Sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2025 (preplanned trading).
• Footnote F2: Multiple executions; the filer can provide per-trade breakdown to the SEC, issuer, or a security holder upon request.
• Shares owned after transaction: not specified in the supplied details.

Context A 10b5-1 plan indicates this sale was prearranged under an approved trading plan, which often reflects scheduled liquidity rather than an ad hoc decision. Sales are generally less informative than insider purchases about confidence in future prospects; this filing documents a routine, preplanned disposition rather than an exercise, grant, or gift.